Review



deep brain stimulation responsive subthalamo  (Hirschmann)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Hirschmann deep brain stimulation responsive subthalamo
    Deep Brain Stimulation Responsive Subthalamo, supplied by Hirschmann, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/deep brain stimulation responsive subthalamo/product/Hirschmann
    Average 86 stars, based on 1 article reviews
    deep brain stimulation responsive subthalamo - by Bioz Stars, 2026-06
    86/100 stars

    Images



    Similar Products

    subthalamic nucleus deep brain stimulation  (Beijing Tiantan Biological)
    86
    Beijing Tiantan Biological subthalamic nucleus deep brain stimulation
    Short-term (1 year) and long-term (3 years) dyskinesia outcomes, other motor outcomes, quality of life, neuropsychological outcomes, and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent <t>subthalamic</t> nucleus deep brain <t>stimulation</t> (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; A-iii ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv) ), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i ), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction).
    Subthalamic Nucleus Deep Brain Stimulation, supplied by Beijing Tiantan Biological, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/subthalamic nucleus deep brain stimulation/product/Beijing Tiantan Biological
    Average 86 stars, based on 1 article reviews
    subthalamic nucleus deep brain stimulation - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    deep brain stimulation  (Boston Scientific Corporation)
    86
    Boston Scientific Corporation deep brain stimulation
    Short-term (1 year) and long-term (3 years) dyskinesia outcomes, other motor outcomes, quality of life, neuropsychological outcomes, and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent <t>subthalamic</t> nucleus deep brain <t>stimulation</t> (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; A-iii ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv) ), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i ), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction).
    Deep Brain Stimulation, supplied by Boston Scientific Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/deep brain stimulation/product/Boston Scientific Corporation
    Average 86 stars, based on 1 article reviews
    deep brain stimulation - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    bilateral subthalamic nucleus deep brain stimulation dbs  (Wolters Kluwer Health)
    86
    Wolters Kluwer Health bilateral subthalamic nucleus deep brain stimulation dbs
    Short-term (1 year) and long-term (3 years) dyskinesia outcomes, other motor outcomes, quality of life, neuropsychological outcomes, and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent <t>subthalamic</t> nucleus deep brain <t>stimulation</t> (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; A-iii ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv) ), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i ), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction).
    Bilateral Subthalamic Nucleus Deep Brain Stimulation Dbs, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bilateral subthalamic nucleus deep brain stimulation dbs/product/Wolters Kluwer Health
    Average 86 stars, based on 1 article reviews
    bilateral subthalamic nucleus deep brain stimulation dbs - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    deep brain stimulation dbs surgery  (Beijing Tiantan Biological)
    86
    Beijing Tiantan Biological deep brain stimulation dbs surgery
    Short-term (1 year) and long-term (3 years) dyskinesia outcomes, other motor outcomes, quality of life, neuropsychological outcomes, and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent <t>subthalamic</t> nucleus deep brain <t>stimulation</t> (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; A-iii ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv) ), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i ), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction).
    Deep Brain Stimulation Dbs Surgery, supplied by Beijing Tiantan Biological, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/deep brain stimulation dbs surgery/product/Beijing Tiantan Biological
    Average 86 stars, based on 1 article reviews
    deep brain stimulation dbs surgery - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    deep brain stimulators  (Boston Scientific Corporation)
    86
    Boston Scientific Corporation deep brain stimulators
    Short-term (1 year) and long-term (3 years) dyskinesia outcomes, other motor outcomes, quality of life, neuropsychological outcomes, and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent <t>subthalamic</t> nucleus deep brain <t>stimulation</t> (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; A-iii ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv) ), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i ), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction).
    Deep Brain Stimulators, supplied by Boston Scientific Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/deep brain stimulators/product/Boston Scientific Corporation
    Average 86 stars, based on 1 article reviews
    deep brain stimulators - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    deep brain stimulation responsive subthalamo  (Hirschmann)
    86
    Hirschmann deep brain stimulation responsive subthalamo
    Short-term (1 year) and long-term (3 years) dyskinesia outcomes, other motor outcomes, quality of life, neuropsychological outcomes, and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent <t>subthalamic</t> nucleus deep brain <t>stimulation</t> (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; A-iii ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv) ), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i ), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction).
    Deep Brain Stimulation Responsive Subthalamo, supplied by Hirschmann, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/deep brain stimulation responsive subthalamo/product/Hirschmann
    Average 86 stars, based on 1 article reviews
    deep brain stimulation responsive subthalamo - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    deep brain stimulation  (Hirschmann)
    86
    Hirschmann deep brain stimulation
    Short-term (1 year) and long-term (3 years) dyskinesia outcomes, other motor outcomes, quality of life, neuropsychological outcomes, and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent <t>subthalamic</t> nucleus deep brain <t>stimulation</t> (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; A-iii ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv) ), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i ), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction).
    Deep Brain Stimulation, supplied by Hirschmann, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/deep brain stimulation/product/Hirschmann
    Average 86 stars, based on 1 article reviews
    deep brain stimulation - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    deep brain stimulation system  (Abbott Laboratories)
    86
    Abbott Laboratories deep brain stimulation system
    Short-term (1 year) and long-term (3 years) dyskinesia outcomes, other motor outcomes, quality of life, neuropsychological outcomes, and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent <t>subthalamic</t> nucleus deep brain <t>stimulation</t> (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; A-iii ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv) ), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i ), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction).
    Deep Brain Stimulation System, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/deep brain stimulation system/product/Abbott Laboratories
    Average 86 stars, based on 1 article reviews
    deep brain stimulation system - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Short-term (1 year) and long-term (3 years) dyskinesia outcomes, other motor outcomes, quality of life, neuropsychological outcomes, and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent subthalamic nucleus deep brain stimulation (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; A-iii ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv) ), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i ), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction).

    Journal: Clinical Interventions in Aging

    Article Title: Long-Term Surgical Outcomes and Influential Factors of Subthalamic Nucleus Deep Brain Stimulation for Dyskinesia in Parkinson’s Disease: A 3-Year Longitudinal Cohort Study

    doi: 10.2147/CIA.S600031

    Figure Lengend Snippet: Short-term (1 year) and long-term (3 years) dyskinesia outcomes, other motor outcomes, quality of life, neuropsychological outcomes, and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent subthalamic nucleus deep brain stimulation (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; A-iii ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv) ), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i ), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction).

    Article Snippet: The flowchart details the selection process for a study on Parkinson's patients with levodopa-induced dyskinesia who received subthalamic nucleus deep brain stimulation at Beijing Tiantan Hospital.

    Techniques: Functional Assay

    Relative changes (%) from baseline to short (1 year) term, baseline to long (3 years) term, and short (1 year) term to long (3 years) term dyskinesia outcomes; other motor outcomes; quality of life; neuropsychological outcomes; and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent subthalamic nucleus deep brain stimulation (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; ( A-iii) ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv )), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i )), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA or Friedman test, as appropriate, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA or Friedman test, as appropriate, with post hoc pairwise comparisons adjusted by Bonferroni correction).

    Journal: Clinical Interventions in Aging

    Article Title: Long-Term Surgical Outcomes and Influential Factors of Subthalamic Nucleus Deep Brain Stimulation for Dyskinesia in Parkinson’s Disease: A 3-Year Longitudinal Cohort Study

    doi: 10.2147/CIA.S600031

    Figure Lengend Snippet: Relative changes (%) from baseline to short (1 year) term, baseline to long (3 years) term, and short (1 year) term to long (3 years) term dyskinesia outcomes; other motor outcomes; quality of life; neuropsychological outcomes; and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent subthalamic nucleus deep brain stimulation (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; ( A-iii) ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv )), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i )), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA or Friedman test, as appropriate, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA or Friedman test, as appropriate, with post hoc pairwise comparisons adjusted by Bonferroni correction).

    Article Snippet: The flowchart details the selection process for a study on Parkinson's patients with levodopa-induced dyskinesia who received subthalamic nucleus deep brain stimulation at Beijing Tiantan Hospital.

    Techniques: Functional Assay